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Background: Amphotericin B deoxycholate remains the treatment of choice for most systemic fungal infections; 
however, its clinical use can be limited by infusion-related side effects and nephrotoxicity. New formulations of 
amphotericin in lipid compounds have been shown to  decrease toxicity. We previously showed that a lipid emulsion 
preparation of amphotericin B deoxycholate was better tolerated than the conventional preparation in  dextrose. 
Therefore, we have now studied the clinical tolerance, renal toxicity and efficacy of higher doses of amphotericin B 
deoxycholate prepared and infused in a fat emulsion (Intralipid 20%). Thus, this report adds information to the previous 
publication. 
Methods: Forty-two patients infected with HIV and suffering oral candidosis entered the study. The patients received 
either amphotericin B deoxycholate-glucose 1 mg/kg/day or amphotericin B deoxycholate-lipid emulsion 1 mg/kg/day 
for 4 days (randomized phase), or amphotericin B deoxycholate-lipid emulsion 2 mg/kg/day or 3 mg/kg/day (escalating- 
dose phase) for 5 days. Clinical (immediate) side effects and renal (creatinine) tolerance were assessed daily; efficacy 
against oral candidosis was measured by using a simple clinical score. Serum levels of amphotericin B were also 
measured. 
Results: None of the patients receiving amphotericin B deoxycholate-lipid emulsion had treatment interrupted, as 
compared to four (36%) in the amphotericin B deoxycholate-glucose group (p 50.01); chills during or after the infusions 
were significantly less frequent in the amphotericin B deoxycholate-lipid emulsion groups than in the amphotericin B 
deoxycholate-glucose group (p=0.03). The increase of creatininemia during treatment was significantly higher for 
patients receiving amphotericin B deoxycholate-glucose than for those receiving amphotericin B deoxycholate-lipid 
emulsion (p=O.OOl). The number of patients who had a creatininemia 218 mg/L during treatment was significantly higher 
in both the amphotericin B deoxycholate-glucose group (36%) and in  the group receiving the highest dose of 
amphotericin B deoxycholate-lipid emulsion than in other groups (~50.06). 
The serum concentrations of amphotericin B were lower for the amphotericin B deoxycholate-lipid emulsion regimen 
than for the amphotericin B deoxycholate-glucose regimen at the same dose of 1 mg/kg/day, but increased with the 
dose. 
The change of the oral candidosis score was similar for the same dose of 1 mg/kg/day of amphotericin B deoxycholate 
infused in  either glucose or lipid emulsion; higher doses of amphotericin B deoxycholate-lipid emulsion were more 
efficacious (p=0.009) and this efficacy seemed to increase with the dose (p=0.06). 
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Conclusions: The clinical and renal tolerance of arnphotericin B deoxycholate are improved when the drug is directly 
prepared and infused in lipid emulsion (Intralipid) and this preparation allows for greater dosage, up to  3 rng/kg/day, 
with resultant greater efficacy. This preparation is simple and cost-effective (approximately 7 US $ per 50 rng of 
amphotercin B) and could be clinically compared to  other formulations of amphotericin B. 
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INTRODUCTION 
Systemic and mucosal candidosis are conditions in- 
creasingly being recognized as causes of morbidity and 
mortality in patients with altered immunity [l-31. In 
spite of the recent development of new antifungal 
agents, amphotericin B remains the treatment of choice 
for systemic candidosis. However, clinical use of anipho- 
tericin can be limited by infusion-related side effects, 
nephrotoxicity and electrolyte abnormalities [4-81. 
Also, patients who require treatment with arnpho- 
tericin B tend to be already seriously ill from their 
underlying diseases and thus particularly susceptible to 
drug toxicity. 
New formulations of amphotericin in lipid coni- 
pounds were shown to decrease toxicity [9]. Although 
most preparations have reduced efficacies when com- 
pared with aniphotericin B deoxycholate on a dosage- 
for-dosage basis, their therapeutic indices are improved 
[9-111. A preparation of aniphotericin in parenteral 
lipid emulsion (Intralipid 20%) was demonstrated to 
reduce toxicity in both neutropenic and AIDS patients 
and in experimental models [12-191. Several investi- 
gators have reported a similar therapeutic effect of 
amphotericin in lipid emulsion in comparison with the 
conventional preparation at  the same dose [12,14,17]. 
Therefore, we planned an escalating-dose trial in 
HIV-infected patients with azole-resistant oral candidosis 
in order to investigate the therapeutic range of this fat 
emulsion preparation of aniphotericin B deoxycholate. 
This study is a continuation of our previous study [16] 
and therefore the results of these two phases are given 
together in this paper. 
METHODS 
Patients were eligible if they were aged 18 or over, 
infected with HIV, and had clinically azole-resistant 
oral candidosis. Patients were not included if they were 
pregnant or breast-feeding, had known intolerance 
to amphotericin or Intralipid, pancreatitis, arrythmia, 
hyperlipidemia or serum creatinine concentration above 
12 nig/L, or if they had received treatment with 
amphotericin B deoxycholate in the previous 4 weeks. 
All eligible patients gave signed informed consent. The 
protocol was accepted by the local ethics committee. 
All the patients included in the study were hospitalized 
in our medical unit. For practical reasons, the treatment 
and the observers were not blinded. 
Treatment 
The first phase, consisting of the comparison of ampho- 
tericin B deoxycholate diluted in 5% glucose with 
amphotericin B deoxycholate diluted in Intralipid 
20%, has been described previously [16]. Briefly, the 
powder of amphotericin B deoxycholate (vials of 
50 mg) was directly diluted in a syringe of 50-60 mL 
with 25 mL of Intralipid 20% (in case of dose >50 
mg/day, 50 mL of Intralipid in one syringe are needed 
to dilute consecutively two vials of 50 mg of ampho- 
tericin B deoxycholate); thus the final concentration of 
2 mg amphotericin B in 1 mL of Intralipid was used. 
This preparation was infused, without an in-line filter, 
by using a horizontal electric pump at a rate of 
0.5 mg/kg/h. 
The second phase consisted of an escalating dose 
trial of the lipid emulsion of amphotericin B. The same 
fat emulsion of amphotericin B deoxycholate was given 
at 2 mg/kg/day and 3 mg/kg/day for five consecutive 
days; the rate of infusion was 0.5 mg/kg/h. The doses 
of 2 and then 3 mg/kg/day were planned when the 
independent committee gave consent after examination 
of the results of the previous phase. Standard hydration 
and electrolyte supplementation were systematically 
given. N o  premedication was given before the in- 
fusions. Aniphotericin B deoxycholate was infused into 
the peripheral or central vein. Concurrent drugs, 
including known nephrotoxic medications, were not 
stopped during this protocol. 
Assessment of tolerance 
Clinical tolerance was monitored by using a standard 
data form which checked for sweating, chills, fever 
(rise of more than 1 "C) ,  nausea, pulse rate and blood 
pressure. Biological tolerance was monitored by twice- 
daily electrolyte and creatinine measurements. In addi- 
tion, a full blood count and electrocardiograms were 
obtained on days 1 and 6. Amphotericin B was stopped 
if severe clinical side effects occurred and if the 
creatinine concentration reached 18 mg/L. Paracetamol 
(1 g orally or intravenously) or dexamethasone (4 mg) 
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were given if severe chills or fever occurred during or 
after the infusion. 
Assessment of efficacy 
We used a simple clinical score to monitor daily the 
state of the oral candidosis [16]. Briefly, every day, the 
following sites were inspected for the presence or the 
absence of candidosis: the upper, right and left sides 
of the tongue, the left and right jaws, the two tonsil 
regions and the smooth and hard palate (1naximum~9). 
Each of these sites was rated for confluent (=3), patchy 
(=2) or scattered (=1) lesions. Thus, a clinical score 
could be determined daily. A regression line of the 
variation of the daily scores was constructed for each 
group by using the least squares method (curve fit R2> 
0.90 for each group, p<0.01, data not shown). A swab 
of one or two lesions was taken for mycologic analysis. 
Pharrnacokinetics 
Serum samples obtained daily before (trough), 5 min 
after the end (peak) of the infusion and 12 h after the 
start ofthe infusion were stored at -20°C until assayed. 
Amphotericin B was assayed by high-performance 
liquid chroniatography [20], including saniples of- the 
first phase of the trial. The volume of initial distribution 
(L/kg) was calculated as follows: dose/concentration 
after the infusion. 
Statistics 
As previously calculated [16], 10-11 patients were 
entered in each group. Results were expressed as mean 
k SD. Statistical analysis was done by using the Mann- 
Whitney U test, the Scheffe test and the Kruskall- 
Wallis test as indicated. The data on tinie of the 
creatininemia, as continuous variables, were analyzed 
by using the ANOVA on repeated measures; the data 
on time to the development of renal impairment, 
defined as a creatinine blood 2 18 mg/L, were analyzed 
by the standard Kaplan-Meier method and conipared 
by using the log-rank test. Significance was considered 
established if the p value was less than 0.05 (two-tailed). 
Calculations were done by using SPSS software for 
Macintosh, Chicago. 
An independent committee reviewed summary data 
of each phase of the protocol; the protocol specified 
that the immediate toxicity of amphotericin B deoxy- 
cholate-lipid eniulsion should not be higher than that 
of conventional amphotericin B deoxycholate, and that 
the renal toxicity of amphotericin B deoxycholate- 
lipid emulsion should be less frequent than that of 
conventional amphotericin B deoxycholate. Therefore, 
this committee decided to terminate the trial at  the 
dose of 3 mg/kg/day amphotericin B deoxycholate- 
Intralipid. 
The groups were comparable for demographic variables, 
status of HIV infection, renal function, total white 
blood cell and CD4 cell count, hemoglobin level, 
and the concomitant use of other nephrotoxic drugs 
(aminoglycosides, vancomnycin, foscarnet, sulfonamides) 
(Table 1). However, the clinical score of oral candidosis 
was higher for the two groups with the highest doses 
of amphotericin B deoxycholate-lipid emulsion (Table 
The main results of the study are shown in Table 
2. None of the patients receiving amphotericin I3 
deoxycholate-fat emulsion had treatment interrupted, 
1). 
Table 1 Clinical and laboratory characteristics o f  the patients at entry 
Fungizone-glucose Fungizone-fat eniulsion 
Dose (nig/kg/day) 1 1 2 3 
Number of patients 11 I 1  10 1 0  
Number of patients with AIDS 8 8 7 5 
Age (years) (mean f SD) 3 5 f 7  34f  7 35+8 3 5 f 9  
Weight (kg) (mean f SD) 61 ? 8  53 f 9  51?7 51 f X  
An tire troviral drugs 5 7 5 9 
Nephrotoxic drugs 5 6 5 9 
Concurrent treatment (No. o f  patients) 
Creatinine (nig/L) (meanfSD) 921.4 X.8f2.2 7 . 3 2 1 3  7.1 f l . 1  
White cell count (xlO'/L) (meanfSD) 3.4k1.7 2.8f1.4 3.2k3.2 3 .4f1 .2  
CD4 count (x 106/L) (tneanfSD) 1 2 0 f l h l  48 2 88 45 f 88 23 2 27 
Hemoglobin (g/L) (nieankSD) 10.9f2.6 10.7 i 2.1 1 1 . 7 f 2  10.7 k 2.2 
Platelet count (x 106/L) (meanfSD) 155.1 k78 155.4 +lo5 1 3 5 f 7 1  132k71 
12.6k 8.1* Clinical score of oral candidosis (mean? SD) 6 f 7  6.3f4.4 10.8f 7.5" 
Number of patients with Cundida ulbicuns strain 9 10 9 7 
*p<O.OS versus the two other groups. 
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Table 2 Clinical and laboratory toxicity and efiicacy 
~ ~ 
Fungizone-glucose Fungizone-fat emulsion 
Dose (nig/kg/day) 
No. of patients 
No. having interruption of treatment (55) 
Fever per infision (mean +_ SD) 
Chills per infusion (mean f SD) 
No of patients with creatinine 218 mg/L 
Change in leukocytosis (x 106/L) (meant  SD) 
Change in haemoglobin (g/L) (meankSD) 
Change in platelets (x 106/L) (meanfSD) 
Change of the clinical score of oral candidosis 
during the treatment (%) 
(meaniSD of regression line) 
1 
11 
4 (36%) 
0.31-0.3 
0.4Ilr0.3' 
4 (36%) 
0.9i1.6 
-9.5+41 
-0.4i-1.9 
-1.151.7 
1 
11 
0 
0.02+0.07^ 
0.02?0.07' 
0 
0.61 f l . l  
-0.2921.1 
-17.7 i. 46 
-1 51.5 
2 
10 
0 
0.3i0.3" 
0 .2 i0 .3  
0 
-0.09 50.08 
-0.77f1.4 
-22 f 31 
-2.ii-1.9 
3 
1 0 
0 
0.46+0.25h 
0.24+0.26 
2 (20%)d 
0.6952.8 
-1.2f2 
-36.2 f 34 
-2.7f2.2' 
'p=0.05; "p=0.007 versus the three other groups; 'p'0.03. 
dp=0.21 between fungizone-glucose and fungizonefat emulsion 3 nig/kg/day and, p=0.04 and ~ 4 . 0 6  between hngizone-glucose and 
fungizone-fat emulsion 1 mg/kg/day and 2 mg/kg/day respectively 
cp=0.05 
as compared to four (36%) in the amphotericin B 
deoxycholate-glucose group (p 50.01). Fever during 
infusions was less frequent in the amphotericin B 
deoxycholate-fat emulsion 1 mg/kg group than in the 
other groups (pr0.007); however, no difference was 
observed between the aniphotericin B deoxycholate- 
glucose group and the highest dose with amphotericin 
B deoxycholate-Intralipid. Chills were significantly less 
kequent in the amphotericin B deoxycholate-lipid 
emulsion groups than in the amphotericin B deoxy- 
cholate-glucose group ( ~ ~ 0 . 0 3 ) .  Neither change nor 
abnormalities were detected during and after the in- 
fusions throughout the investigation in pulse rate, blood 
pressure, electrolytes, blood cell counts and electro- 
cardiograms. 
The evolution of renal function, measured as 
creatininemia, is depicted in Figure 1, upper panel. The 
increase of creatininemia during this protocol was signi- 
ficantly higher for patients receiving amphotericin B 
deoxycholate-glucose than for those receiving anipho- 
tericin B deoxycholate-lipid emulsion (p=0.001). 
Although the creatininemia increased more for the 
3 mg/kg/day amphotericin B deoxycholate-fat emul- 
sion group than for the 3 mg/kg/day and the 2 
mg/ kg/day amphotericin B deoxycliolate-fat emulsion 
groups, a significant difference was only reached on day 
5 of the treatment (the last infusion) (y<0.05). N o  
differences were detected between the 1 mg/kg/day 
and the 2 mg/kg/day arnphotericin B deoxycholate- 
fat emulsion groups (p=0.72); there was a significant 
difference in renal toxicity between the 2 mg/kg/day 
and the 3 mg/kg/day amphotericin B deoxycholate fat 
emulsion groups ( ~ ~ 0 . 0 3 ) .  The number of patients 
who had a creatininemia 218 mg/L was significantly 
higher in both the amphotericin B deoxycholate- 
glucose group (36%) and in the group receiving the 
highest dose of amphotericin B deoxycholate-lipid 
emulsion (20%) than in other groups (p 50.06) (Table 
2). The cuniulative probability of this event is depicted 
in Figure 1, lower panel; clearly, the amphotericin B 
deoxycholate-glucose regimen caused a more frequent 
and more precocious renal impairment than the 
aniphotericin B deoxycholate-fat emulsion regimens 
(log-rank test, p ~0.044);  furthermore, this cumulative 
probability for the highest dose of 3 mg/kg/day was 
significantly lower than that of amphotericin B deoxy- 
cholate-glucose (22% versus 5496, ~ ~ 0 . 0 5 ) .  Since the 
cumulative probability for the 3 mg/kg/day ampho- 
tericin B deoxycholate-fat emulsion reached 20%, the 
independent committee did not allow the next step in 
the study which was planned to test higher dosage. 
Although this study was not designed to investigate 
pharmacokinetics, serum amphotericin B concentra- 
tions were measured in 347 samples obtained from 
each group of patients (Figure 2). The concentrations 
of amphotericin B were lower for the amphotericin 
B deoxycholate-fat emulsion regimen than for the 
amphotericin B deoxycholate regimen at the same 
dose of 1 mg/kg/day. However, the concentrations of 
amphotericin B increased with the dose of ainpho- 
tericin B deoxycholate-fat emulsion. Thus, the initial 
volume of distribution of aniphotericin B was lower for 
the amphotericin B deoxycholate-glucose regimen 
than for the amphotericin B deoxycholate-fat emulsion 
regimens (0.71 k0.24 L/kg versus 1.48k0.5 L/kg, 
1.16k0.6 L/kg and 1.4k0.4 L/kg for the 1 mg/kg, 
2 mg/kg and 3 mg/kg amphotericin B deoxycholate- 
fat emulsion regimens, respectively; p=0.005). 
The efficacy of these amphotericin B regimens was 
evaluated clinically by using a simple score of the oral 
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Figure 1 Evolution of creatininemia during amphotericin 
B treatment (upper panel) and occurrence of the 
creatininemia above 18 mg/L according to treatnlcnt group 
(plotted with Kaplan-Meier curves) (lower panel): 
A=amphotericin B deoxycholate-glucose T nig/kg/day; 
B=aniphotericin B-lipid emulsion 1 mg/kg; 
C=amphotcricin B-lipid emulsion 2 nig/kg; 
D=amphotcricin B-lipid eniulsion 3 nig/kg. 
Upper panel: ANOVA on repeated measures, p=O.OOl ,  and 
p<O.05 on day 5 for regimens A versus B or C. Lower 
panel: log-rank test, p=0.0044, and p=0.05 between 
regimens A and B. 
2.5 3 l  
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Figure 2 Pharmacokinetics of amphotericin in serum 
(mean data of each group): 
A= amphotericin B deoxycholatc-glucose 1 mg/kg/day; 
B= amphotericin B-lipid emulsion 1 rng/kg; 
C=aniphotericin B-lipid emulsion 2 nig/kg; 
D=aniphotericin B-lipid emulsion 3 nig/kg. 
candidosis. T h e  slope of change of this score over the 
5 days of treatment was similar for the sanie dose of 
1 mg/kg/day of amphotericin B deoxycholate infused 
either in glucose or  in  Intralipid (Table 2). Further- 
more, higher doses of arnphotericin B deoxycholate 
were more efficacious (p=0.009) and this efficacy 
seemed to increase with the dose of  amphotericin B 
deoxycholate-fat emulsion ( ~ ~ 0 . 0 6 ) .  
DISCUSSION 
We and others have clearly shown that, at the same 
dose, amphotericin B deoxycholate prepared in  a 
well-known lipid emulsion (Intralipid 20%)) was less 
toxic than conventional amphotericin B deoxycholate 
[14-17,19,21-271. However, several author$ did not 
find this amelioration [28-3O]. Although this issue 
remains controversial, one explanation could be that 
the modalities of both preparation (too large a volume 
of lipid emulsion) and infusion (vertical but not 
horizontal, non-calibrated rate of infusion) used by 
these authors were quite different from our  recommen- 
dations (see Method). Therefore, taking into account 
our  observations, we planned this study to  investigate 
the possibility of increasing the dose of amphotericin B 
deoxycholate. 
At the dose of 2 mg/kg/day, this lipid-based 
formulation of amphotericin B was as well tolerated as 
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the 3 mg/kg/day regimen; in particular, no differences 
in creatinine blood levels were seen between these 
two regimens. Furthermore, we found that a dosage 
of 3 mg/kg/day of amphotericin B deoxycholate-fat 
emulsion could be used. At this dose, no treatment 
courses were stopped, the immediate clinical side 
effects during or after the infusions were less frequent 
and, moreover, renal function impairment was less pro- 
nounced and occurred less frequently than with con- 
ventional 1 mg/kg/day amphotericin B deoxycholate. 
The serum concentrations of amphotericin B were 
lower with the amphotericin B deoxycholate-lipid 
emulsion regimen than with the amphotericin B 
deoxycholate-glucose regimen at the same dose of 
1 mg/kg/day but increased with the dose. Although we 
did not precisely investigate the pharmacokinetics of 
amphotericin B deoxycholate-lipid emulsion, our 
observations were concordant with previous data 
[16,19,31] which demonstrated an increase of the 
volume of distribution of amphotericin B when infused 
with this lipid emulsion. The serum concentrations of 
amphotericin B were lower with the amphotericin B 
deoxycholate-lipid emulsion regimen than with the 
amphotericin B deoxycholate-glucose regimen at the 
same dose of 1 mg/kg/day but increased with the dose. 
These lower concentrations could partly explain the 
lower rate of side effects observed with the ampho- 
tericin B deoxycholate-lipid emulsion. According to 
experimental data and clinical observations [24,33-361, 
it is quite probable that the diffusion of amphotericin 
€3 diluted in the lipid emulsion is wide and not limited 
to some rich reticuloendothelial system tissues [37]. 
Finally, the clinical activity (based on scoring the 
candidal lesions in the mouth) of amphotericin B 
deoxycholate-lipid eniulsion was found, on a dosage- 
for-dosage basis, to be at least as effective as that of 
conventional amphotericin B deoxycholate and, further- 
more, higher doses appeared to be more effective on 
mucosal candidal infection in immunocompromised 
patients. This finding is in complete accordance with 
in vitro and in vivo experimental data [38-41] and 
clinical experience [25,33,38]. However, this trial was 
a short-course treatment trial and was not planned to 
investigate precisely the efficacy of this preparation for 
the treatment of candidal tissue infections; further 
clinical studies are therefore warranted. 
The possibility of high doses of amphotericin €3 is 
of interest for the treatment of resistant fungal infections 
[24,42-441. Thus, our results warrant further clinical 
trials to compare the effectiveness of this formulation 
with other lipid-based formulations of amphotericin B 
[9]. In addition, the results of this study clearly show 
that the full dose of amphotericin B deoxycholate 
diluted in the lipid emulsion could be administered 
immediately and that the usual escalating-dose schedule 
could be omitted. These positive therapeutic results, 
combined with favorable pharmacokinetics and toler- 
ance of amphotericin B deoxycholate-lipid emulsion, 
suggest that the use of loading doses or high doses for 
short courses of treatment could be realizable. 
We conclude that the clinical and renal tolerance 
of amphotericin B deoxycholate is improved when the 
drug is directly prepared and infused in lipid emulsion 
(Intralipid) and that this preparation allows for higher 
dosage, up to 3 mg/kg/day. In addition, its therapeutic 
index on candidal infection is not altered versus 
conventional amphotericin B deoxycholate and increases 
with the dose. This preparation is simple and cost- 
effective (approximately 7 US $ per 50 mg of ampho- 
tercin B) and should be clinically compared to other 
formulations of amphotericin B. 
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